Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies is a clinical stage biopharmaceutical company targeting solid tumors with two promising drug technologies. The completion of the OST-HER2 clinical data package submission, multiple regulatory designations and strong biomarker support for potential accelerated FDA approval in 2026 should greatly increase investor confidence in the stock. The potential sale of a Priority Review Voucher valued at approximately $205M adds even more value to the company and could serve as a non-dilutive financing opportunity.

Bears say

OS Therapies is strategically shifting from clinical signal generation towards regulatory execution, with key catalysts such as completion of regulatory meetings in Q2 2026 and initiation of the global Phase 3 trial in Q3 2026, but faces significant risks as its pipeline is still in preclinical development and its potential PRV monetization may not materialize. Additionally, there is limited financial information available for the company, making it difficult to evaluate its overall financial health and potential for profitability.

OSTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, OSTX has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.